company background image
ONC logo

Oncolytics Biotech TSX:ONC Stock Report

Last Price

CA$1.51

Market Cap

CA$113.8m

7D

11.9%

1Y

-30.7%

Updated

03 Mar, 2024

Data

Company Financials +

ONC Stock Overview

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer.

ONC fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Oncolytics Biotech Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Oncolytics Biotech
Historical stock prices
Current Share PriceCA$1.51
52 Week HighCA$4.49
52 Week LowCA$1.20
Beta1.48
1 Month Change-3.21%
3 Month Change-20.11%
1 Year Change-30.73%
3 Year Change-55.59%
5 Year Change-43.87%
Change since IPO-89.40%

Recent News & Updates

We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully

Feb 23
We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully

Recent updates

We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully

Feb 23
We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully

Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans?

Nov 10
Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans?

We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully

Jul 07
We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully

Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans?

Mar 24
Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans?

Is Oncolytics Biotech (TSE:ONC) In A Good Position To Invest In Growth?

Dec 09
Is Oncolytics Biotech (TSE:ONC) In A Good Position To Invest In Growth?

We're Keeping An Eye On Oncolytics Biotech's (TSE:ONC) Cash Burn Rate

Aug 25
We're Keeping An Eye On Oncolytics Biotech's (TSE:ONC) Cash Burn Rate

Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation

May 12
Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation

We Think Oncolytics Biotech (TSE:ONC) Can Afford To Drive Business Growth

Dec 02
We Think Oncolytics Biotech (TSE:ONC) Can Afford To Drive Business Growth

We Think Oncolytics Biotech (TSE:ONC) Can Afford To Drive Business Growth

Aug 05
We Think Oncolytics Biotech (TSE:ONC) Can Afford To Drive Business Growth

Companies Like Oncolytics Biotech (TSE:ONC) Are In A Position To Invest In Growth

Apr 15
Companies Like Oncolytics Biotech (TSE:ONC) Are In A Position To Invest In Growth

We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully

Dec 31
We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully

Shareholder Returns

ONCCA BiotechsCA Market
7D11.9%-1.4%0.7%
1Y-30.7%-25.4%2.4%

Return vs Industry: ONC underperformed the Canadian Biotechs industry which returned -25.4% over the past year.

Return vs Market: ONC underperformed the Canadian Market which returned 2.4% over the past year.

Price Volatility

Is ONC's price volatile compared to industry and market?
ONC volatility
ONC Average Weekly Movement10.9%
Biotechs Industry Average Movement11.4%
Market Average Movement8.5%
10% most volatile stocks in CA Market17.9%
10% least volatile stocks in CA Market3.2%

Stable Share Price: ONC's share price has been volatile over the past 3 months.

Volatility Over Time: ONC's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199829Matt Coffeyhttps://www.oncolyticsbiotech.com

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer.

Oncolytics Biotech Inc. Fundamentals Summary

How do Oncolytics Biotech's earnings and revenue compare to its market cap?
ONC fundamental statistics
Market capCA$113.85m
Earnings (TTM)-CA$32.36m
Revenue (TTM)n/a

0.0x

P/S Ratio

-3.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ONC income statement (TTM)
RevenueCA$0
Cost of RevenueCA$0
Gross ProfitCA$0
Other ExpensesCA$32.36m
Earnings-CA$32.36m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.43
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ONC perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.